Ondine Biomedical (LSE:OBI) Cash-to-Debt : 6.08 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ondine Biomedical Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ondine Biomedical's cash to debt ratio for the quarter that ended in Jun. 2023 was 6.08.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Ondine Biomedical could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Ondine Biomedical's Cash-to-Debt or its related term are showing as below:

LSE:OBI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.17 Max: 41.1
Current: 6.08

During the past 13 years, Ondine Biomedical's highest Cash to Debt Ratio was 41.10. The lowest was 0.01. And the median was 0.17.

LSE:OBI's Cash-to-Debt is ranked worse than
50.43% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs LSE:OBI: 6.08

Ondine Biomedical Cash-to-Debt Historical Data

The historical data trend for Ondine Biomedical's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Ondine Biomedical Cash-to-Debt Chart

Ondine Biomedical Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

0.07

0.01

0.02

41.10

14.64

Ondine Biomedical Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															0.02	41.10	29.10	14.64	6.08

Competitive Comparison of Ondine Biomedical's Cash-to-Debt

For the Biotechnology subindustry, Ondine Biomedical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ondine Biomedical's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Ondine Biomedical's Cash-to-Debt falls into.

Ondine Biomedical Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Ondine Biomedical's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	7.932	/	(0.217	+	0.325)
	=	14.63

Ondine Biomedical's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.646	/	(0.239	+	0.196)
	=	6.08

Ondine Biomedical (LSE:OBI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Ondine Biomedical Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical (LSE:OBI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (LSE:OBI) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OBIMF:USA

Address

1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6

Website

https://www.ondinebio.com

Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.

Ondine Biomedical (LSE:OBI) Headlines

No Headlines